Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
J Clin Med ; 13(8)2024 Apr 12.
Article in English | MEDLINE | ID: mdl-38673512

ABSTRACT

Background: Epidemiological data regarding the incidence and mortality of sepsis are scarcely available. The present study aimed to delineate the epidemiology of sepsis and related mortality among patients hospitalized in Sicily, Italy. Methods: Data on the discharge forms of all patients with sepsis in all Sicilian hospitals from January 2016 to December 2020 were retrospectively collected. Results: In Sicily, 15,373 hospitalizations associated with sepsis occurred from 2016 to 2020, with an overall in-hospital mortality rate of 36.3%. The percentage of hospitalizations associated with sepsis represented 0.65% of all admissions, with an increase over the years. Most patients were admitted to non-surgical and non-infectious disease units, accounting for 50.3% of total admissions. Stratification of patients according to age, intensive care unit (ICU) admission, and presence of septic shock revealed variations in in-hospital mortality rates. Among adult ICU-admitted patients with septic shock, mortality was highest at 81.0%, followed by non-ICU adult patients with septic shock (63.5%), ICU pediatric patients with septic shock (56.7%), ICU adult patients without septic shock (43.9%), non-ICU pediatric patients with septic shock (37.9%), non-ICU adult patients without septic shock (17.9%), ICU pediatric patients without septic shock (10.4%), and non-ICU pediatric patients without septic shock (1%).

2.
Antibiotics (Basel) ; 12(8)2023 Aug 17.
Article in English | MEDLINE | ID: mdl-37627748

ABSTRACT

Bone and joint infections (BJIs) caused by multidrug-resistant gram-negative bacteria are becoming a concern due to limited therapeutic options. Although not approved for these indications, an ever-growing amount of evidence supports the efficacy and safety of ceftazidime-avibactam as a therapy for osteomyelitis and prosthetic joint infections. Here, we present three cases of difficult-to-treat resistant Pseudomonas aeruginosa osteomyelitis that were successfully treated with ceftazidime-avibactam alone or in combination therapy with fosfomycin and amikacin. Ceftazidime-avibactam was prescribed at a daily dose of 2.5 g every 8 h for 42 days in all cases. One potential drug-related adverse effect was observed, i.e., Clostridioides difficile infection, which occurred after fourteen days of treatment with ceftazidime-avibactam.

3.
Heliyon ; 9(8): e18537, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37533984

ABSTRACT

Here, we describe the case of a naïve HIV late presenter female African patient with progressive disseminated histoplasmosis and a severe life-threatening clinical picture in a non-endemic area. She had not visited Africa in the past decade. She developed a reactive hemophagocytic lymphohistiocytosis and an acute psychiatric disorder. Histoplasmosis was diagnosed after two bone marrow biopsies. Therapy with liposomal amphotericin B resulted in rapid and progressive improvements in blood examinations and clinical conditions, including the disappearance of psychiatric disorders. The characteristics of our case were compared with those of all other cases of hemophagocytic syndrome secondary to histoplasmosis in HIV-positive patients reported in PubMed. In conclusion, clinicians outside endemic areas should evaluate histoplasmosis as a cause of severe clinical picture, especially in a patient with a travel history to an endemic area, even after many years, considering the possible reactivation of latent infection.

4.
J Infect Public Health ; 16(9): 1518-1524, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37393129

ABSTRACT

BACKGROUND: Very few data are available in the literature regarding tuberculosis (TB) hospitalization, and few studies have reported the clinical characteristics and comorbidities of admitted patients and burden and cost of hospitalization. In our study, we described the occurrence of TB hospital admissions in the southern Italian region of Sicily over 13 years (2009-2021), explored the characteristics of patients with TB, and determined the comorbidities associated with mortality. METHOD: Data on the hospital discharge of all patients with TB hospitalized in all Sicilian hospitals were retrospectively collected from hospital standard discharge forms. Age, sex, nationality, length of hospital stay, comorbidities, and TB localization were evaluated using univariate analysis according to in-hospital mortality. The factors associated with mortality were included in the logistic regression model. RESULTS: In Sicily, 3745 people were hospitalized for TB, with 5239 admissions and 166 deaths from 2009 to 2021. Most hospitalizations involved Italian-born people (46.3%), followed by African-born people (32.8%) and Eastern European-born people (14.1%). The average hospitalization cost was EUR 5259 ± 2592, with a median length of stay of 16 days (interquartile range, 8-30) days. Multivariate analysis showed that the development of acute kidney failure (adjusted odds ratio [aOR]=7.2, p < 0.001), alcohol consumption (aOR=8.9, p = 0.001), malignant tumors (aOR=2.1, p = 0.022), human immunodeficiency virus infection (aOR=3.4, p < 0.001), sepsis (aOR=15.2, p < 0.001), central nervous system involvement (aOR=9.9, p < 0.001), and miliary TB (aOR=2.5, p = 0.004) were independent predictors of mortality. CONCLUSION: TB in Sicily remains an important cause of hospitalization. HIV infection and comorbidities may complicate patient management and worsen patient outcomes.


Subject(s)
HIV Infections , Tuberculosis , Humans , Retrospective Studies , Sicily/epidemiology , Tuberculosis/epidemiology , Hospitalization , Hospital Mortality
5.
Antibiotics (Basel) ; 12(5)2023 Apr 30.
Article in English | MEDLINE | ID: mdl-37237740

ABSTRACT

Clostridioides difficile infection (CDI) is a significant cause of morbidity and mortality, mostly in frail patients. Notification is not mandatory in Italy, and data on incidence, risk of death, and recurrence are lacking. The purpose of this study was to determine CDI incidence and risk factors for mortality and recurrence. The "ICD-9 00845" code in hospital-standardized discharged forms (H-SDF) and microbiology datasets were used to retrieve CDI cases at Policlinico Hospital, Palermo between 2013 and 2022. Incidence, ward distribution, recurrence rate, mortality, and coding rate were considered. The risk of death and recurrence was predicted through multivariable analysis. There were 275 CDIs, 75% hospital-acquired, the median time between admission and diagnosis was 13 days, and the median stay was 21 days. Incidence increased from 0.3 to 5.6% (an 18.7-fold increase) throughout the decade. Only 48.1% of cases were coded in H-SDF. The rate of severe/severe-complicated cases increased 1.9 times. Fidaxomicin was used in 17.1% and 24.7% of cases overall and since 2019. Overall and attributable mortalities were 11.3% and 4.7%, respectively. Median time between diagnosis and death was 11 days, and recurrence rate was 4%. Bezlotoxumab was administered in 64% of recurrences. Multivariable analysis revealed that only hemodialysis was associated with mortality. No statistically significant association in predicting recurrence risk emerged. We advocate for CDI notification to become mandatory and recommend coding CDI diagnosis in H-SDF to aid in infection rate monitoring. Maximum attention should be paid to preventing people on hemodialysis from getting CDI.

7.
Risk Anal ; 42(10): 2275-2290, 2022 Oct.
Article in English | MEDLINE | ID: mdl-35229333

ABSTRACT

Critical infrastructures are increasingly reliant on information and communications technology (ICT) for more efficient operations, which, at the same time, exposes them to cyber threats. As the frequency and severity of cyberattacks are increasing, so are the costs of critical infrastructure security. Efficient allocation of resources is thus a crucial issue for cybersecurity. A common practice in managing cyber threats is to conduct a qualitative analysis of individual attack scenarios through risk matrices, prioritizing the scenarios according to their perceived urgency and addressing them in order until all the resources available for cybersecurity are spent. Apart from methodological caveats, this approach may lead to suboptimal resource allocations, given that potential synergies between different attack scenarios and among available security measures are not taken into consideration. To overcome this shortcoming, we propose a quantitative framework that features: (1) a more holistic picture of the cybersecurity landscape, represented as a Bayesian network (BN) that encompasses multiple attack scenarios and thus allows for a better appreciation of vulnerabilities; and (2) a multiobjective optimization model built on top of the said BN that explicitly represents multiple dimensions of the potential impacts of successful cyberattacks. Our framework adopts a broader perspective than the standard cost-benefit analysis and allows the formulation of more nuanced security objectives. We also propose a computationally efficient algorithm that identifies the set of Pareto-optimal portfolios of security measures that simultaneously minimize various types of expected cyberattack impacts, while satisfying budgetary and other constraints. We illustrate our framework with a case study of electric power grids.

8.
Data Brief ; 25: 104243, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31367666

ABSTRACT

This article presents the risk assessment of a mixing tank mechanical system based on the failure probabilities of the components. Possible component failures can cause accidents which evolve over multiple time stages and can lead to system failure. The consequences of these accident scenarios are analyzed by quantifying the failure probabilities and severity of their outcomes. Illustrative costs and updated failure probabilities are provided to evaluate preventive safety measures. Data refers to the results of the Bayesian model presented in our research article (Mancuso et al., 2019).

9.
Am J Physiol Gastrointest Liver Physiol ; 307(4): G420-9, 2014 Aug 15.
Article in English | MEDLINE | ID: mdl-24970779

ABSTRACT

Despite well-known intestinal epithelial barrier impairment and visceral hypersensitivity in irritable bowel syndrome (IBS) patients and IBS-like models, structural and physical changes in the mucus layer remain poorly understood. Using a water avoidance stress (WAS) model, we aimed at evaluating whether 1) WAS modified gut permeability, visceral sensitivity, mucin expression, biochemical structure of O-glycans, and related mucus physical properties, and 2) whether Lactobacillus farciminis treatment prevented these alterations. Wistar rats received orally L. farciminis or vehicle for 14 days; at day 10, they were submitted to either sham or 4-day WAS. Intestinal paracellular permeability and visceral sensitivity were measured in vivo. The number of goblet cells and Muc2 expression were evaluated by histology and immunohistochemistry, respectively. Mucosal adhesion of L. farciminis was determined ex situ. The mucin O-glycosylation profile was obtained by mass spectrometry. Surface imaging of intestinal mucus was performed at nanoscale by atomic force microscopy. WAS induced gut hyperpermeability and visceral hypersensitivity but did not modify either the number of intestinal goblet cells or Muc2 expression. In contrast, O-glycosylation of mucins was strongly affected, with the appearance of elongated polylactosaminic chain containing O-glycan structures, associated with flattening and loss of the mucus layer cohesive properties. L. farciminis bound to intestinal Muc2 and prevented WAS-induced functional alterations and changes in mucin O-glycosylation and mucus physical properties. WAS-induced functional changes were associated with mucus alterations resulting from a shift in O-glycosylation rather than from changes in mucin expression. L. farciminis treatment prevented these alterations, conferring epithelial and mucus barrier strengthening.


Subject(s)
Intestinal Mucosa/metabolism , Mucin-2/biosynthesis , Probiotics/therapeutic use , Stress, Psychological/physiopathology , Animals , Colon/metabolism , Corticosterone/blood , Glycosylation , Goblet Cells/physiology , Intestinal Mucosa/microbiology , Lactobacillus/metabolism , Male , Mucus/metabolism , Permeability , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...